A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffer
A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffer
A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
30
Years old
Gender
Male
Therapeutic area :
Blood Disorders
Disease :
Dyslipidemia
Study medication :
V0312
Phase :
Phase II
Start Date :
28 April 2008
End date :
02 September 2008
Study ID :
V00312 CA 201
EudraCT/CTIS number :
2007-006393-29
Send by email